UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017720
Receipt number R000020527
Scientific Title Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer
Date of disclosure of the study information 2015/06/01
Last modified on 2015/05/28 14:05:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer

Acronym

Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer

Scientific Title

Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer

Scientific Title:Acronym

Clinical stusy of induction S-1+Oxaliplatin+/-Cetuximab chemotherapy followed by short-course chemoradiotherapy in locally advanced ugly rectal cancer

Region

Japan


Condition

Condition

locally advanced rectal cancer

Classification by specialty

Surgery in general Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

safety and efficiency of induction chemotherapy(TS-1/L-OHP+/- Cetuximab) followed by chemoradiotherapy and surgery in locally advanced rectal cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

pathologival complete response rate

Key secondary outcomes

Adverse event
Compliance to induction chemotherapy
R0 resection rate
Down-staging rate(T,N stage)
Tumor regression grade
LFS; local recurrence free survival
RFS; Recurrence free survival
OS; Overall survival



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

S-1/Oxaliplatin; treatment dose was decided by body mass index
Cetuximab was used only Kras wild type

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

1) T3 lower rectal cancer with mesorectal fascia involvement
2) T4a or T4b tumors
3) lateral lymph node swelling with the cut-off size larger 5mm measured on axial view at shorter axis.

Key exclusion criteria

inflammatory bowel disease
cardiac disease
medical conditions that would not permit the patient to complete the study

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hidenori Yanagi

Organization

Meiwa Hospital

Division name

Surgery

Zip code


Address

4-31 Agenaruo-cho, Nishinomiya, Hyogo

TEL

+81-798-47-1767

Email

n_beppu@yahoo.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naohito Beppu

Organization

Meiwa Hospital

Division name

Surgery

Zip code


Address

4-31 Agenaruo-cho, Nishinomiya, Hyogo

TEL

+81-798-47-1767

Homepage URL


Email

n_beppu@yahoo.co.jp


Sponsor or person

Institute

Meiwa Hospital department of surgery

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

明和病院(兵庫県)


Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2012 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2012 Year 05 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 05 Month 28 Day

Last modified on

2015 Year 05 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020527


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name